SEARCH

SEARCH BY CITATION

References

  • 1
    Hull PS, Worthington HV, Clerehugh V, Tsirba R, Davies RM, Clarkson JE. The reasons for tooth extractions in adults and their validation. J Dent 1997;25:233237.
  • 2
    Quteish Taani DS. Periodontal reasons for tooth extractions in an adult population in Jordan. J Oral Rehabil 2003;30:110112.
  • 3
    BartoldPM, ed. An update in contemporary periodontics. An Australian Dental Journal Special Supplement. Aust Dent J September 2009.
  • 4
    Seeman E, Delmar PD. Bone quality – the material and structural basis of bone strength and fragility. N Engl J Med 2006;354:22502261.
  • 5
    National Prescriber Service. Maintaining bone health to prevent osteoporotic fractures 2007;53:14.
  • 6
    Roberts WE. Bone physiology, metabolism, and biomechanics in orthodontic practice. In: GraberTM, VanarsdallRLJr, eds. Orthodontics, current principles and techniques. 3rd edn. St. Louis: Mosby-Year Book, 2000:193257.
  • 7
    Reitan K. Effects of force magnitude and direction of tooth movement in different alveolar bone types. Angle Orthod 1964;340344.
  • 8
    Meikle MC. The biology of skeletal tissues. In: Craniofacial development, growth and evolution. Diss: Bateson Publishing, 2002. Chapter 3, pp. 77117.
  • 9
    Kasperk C, Wergedahl J, Strong D, et al. Human bone cell phenotypes differ depending on their skeletal side of origin. J Clin Endocrinol Metab 1995;80:25112517.
  • 10
    Hall BK. The neural crest in development and evolution. Springer Verlay: New York, 1999.
  • 11
    Everts V, Korper W, Jansen DC, et al. Functional heterogeneity of osteoclasts: matrix metalloproteinases participate in osteoclastic resorption of calvarial bone but not resorption of long bones. FASEB J 1999;13:12191230.
  • 12
    Auclair PL, Cuenin P, Kratochvil FJ, Slater LJ, Ellis GL. A clinical and histomorphologic comparison of the central giant cell granuloma and the giant cell tumor. Oral Surg Oral Med Oral Pathol 1988;66:197208.
  • 13
    Dixon RB, Trickler ND, Garetto LP. Bone turnover in elderly canine mandible and tibia. J Dent Res 1997;76:2579.
  • 14
    Romas E. Corticosteroid-induced osteoporosis and fractures. Aust Prescr 2008;31:4549.
  • 15
    NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy. JAMA 2001;285:785795.
  • 16
    General News Osteoporosis. Australian Doctor. 11 July 2008. Available at: http://www.australiandoctor.com.au.
  • 17
    Rosen HN, Moses AC, Garber J, et al. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of a low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000;66:100103.
  • 18
    Taguchi A, Suei Y, Ohtsuka M, Otani K, Tanimoto K, Hollender LG. Relationship between mineral bone density and tooth loss in elderly Japanese women. Dentomaxillofac Radiol 1999;28:219223.
  • 19
    Inagaki K, Kurosu Y, Yamiya T, et al. Low metacarpal bone density, tooth loss and periodontal disease in Japanese women. J Dent Res 2001;80:18181822.
  • 20
    Gur A, Nas K, Kayhan O, et al. The relationship between tooth loss and bone mass in postmenopausal women in Turkey. A multicentre study. J Bone Miner Metab 2003;21:4347.
  • 21
    Earnshaw SA, Keating N, Hosking DJ, et al. Tooth counts do not predict bone mineral density in early postmenopausal Caucasian women. EPIC study group. Int J Epidemiol 1998;27:497483.
  • 22
    Hirai T, Ishijima T, Hashikawa Y, Yajima T. Osteoporosis and reduction of residual ridge in edentulous patients. J Prosthet Dent 1993;69:4956.
  • 23
    Lucas RB. Pathology of tumours of the oral tissues. Churchill Livingston: New York, 1972.
  • 24
    Cheng A, Mavrokokki A, Carter G, et al. The dental implications of bisphosphonates and bone disease. Aust Dent J 2005;50 Suppl 2:S4S13.
  • 25
    Licata AA. Discovery, clinical development and therapeutic uses of bisphosphonates. Ann Pharmacother 2005;39:668677.
  • 26
    Martin TJ, Grin V. Bisphosphonates – mechanism of action. Aust Prescr 2000;23:130132.
  • 27
    Sparidans RW, Twiss IM, Talbot S. Bisphosphonates in bone diseases. Pharm World Sci 1998;20:206213.
  • 28
    Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006;38:617627.
  • 29
    Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002;4:3034.
  • 30
    Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of the action of bisphosphonates. Cancer 2000;88(12 Suppl):29612978.
  • 31
    Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates. A review of 63 cases. J Oral Maxillofac Surg 2004;62:527536.
  • 32
    Kapitolo J, Zuk J. Effects of pamidronate on bone blood flow in oophorectomised rats. Physiol Rev 1998;47:237240.
  • 33
    Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenesis effects of the bisphosphonate compound zoledronic acid. J Pharmocol Exp Ther 2002;302:10551061.
  • 34
    Landesberg R, Cozin M, Cremers S, et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 2008;66:839847.
  • 35
    Tarassott R, Csermilk K. Avascular necrosis of the jaws, risk factors in metastatic cancer patients. J Oral Maxillofac Surg 2003;61:12381239.
  • 36
    Marx RE. Pamidronate (Avedia) and Zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:11151117.
  • 37
    Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003;21:42534254.
  • 38
    Carter GD, Goss AN. Bisphosphonates and avascular necrosis of the jaws. Aust Dent J 2003;48:268.
  • 39
    Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and risk of incidental atrial fibrillation in women. Arch Intern Med 2008;168:826831.
  • 40
    Wysowski DK, Chang JT. Severe bone pain and alendronate. Arch Intern Med 2005;165:346347.
  • 41
    Parkes-Pope T. Spontaneous femur fracture for patients on bisphosphonates. New York Times. 15 July 2008.
  • 42
    Kosla S, Burr D, Cauley J, et al. Bisphosphonate associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:14791491.
  • 43
    Marx RE. Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws. History, etiology, prevention and treatment. Quintessence Publishing Co., 2006.
  • 44
    Mavrokokki T, Cheng A, Stein B, Goss AN. Nature and frequency of bisphosphonate associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415423.
  • 45
    Lo JC, O’Ryan F. Predicting the risk of osteonecrosis with bisphosphonate exposure. (PROBE) study. Kaiser Permanate Northern California Quarterly Newsletter 10:2:1 and 16.
  • 46
    Sedghizadeh PP, Stanley K, Caligiuri M, Hofkes S, Lowry B, Shuler C. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc 2009;140:6166.
  • 47
    Kunchur R, Goss AN. The oral health status of patients on oral bisphosphonates for osteoporosis. Aust Dent J 2008;53:354357.
  • 48
    Goss AN, Bartold PM, Sambrook PM, Hawker P. The nature and frequency of bisphosphonate associated osteonecrosis of the jaws in dental implant patients. The South Australian case series. J Oral Maxillofac Surg 2009 (in press).
  • 49
    Kunchur R, Need A, Hughes H, Goss AN. A preliminary investigation of the CTX test in the identification of patients at risk of bisphosphonate associated ONJ. J Oral Maxillofac Surg 2009;67:11671173.
  • 50
    Bone HG, Hosking D, Devogelaer JP, et al. Ten years experience with alendronate for osteoporosis in post menopausal women. N Eng J Med 2004;350:11891199.
  • 51
    Marx RE. Uncovering the cause of “phossy jaw” circa 1858–1906: oral and maxillofacial surgery closed case files – case closed. J Oral Maxillofac Surg 2008;66:23562363.
  • 52
    Allen MR, Burr DB. Mandible matrix necrosis in beagle dogs after three years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg 2008;66:987994.
  • 53
    Tenenbaum HC, Shelemay A, Girard B, Zohar R, Fitz PC. Bisphosphonates and periodontics: potential applications on regulation of bone mass in the periodontium and other therapeutic/diagnostic uses. State of the Art Review. J Periodontol 2002;73:813822.
  • 54
    McCauley LK, Nohutcu RM. Mediators of periodontal osseous destruction and remodelling: principles and implications for diagnosis and therapy. J Periodontol 2002;73:13771391.
  • 55
    El-Shinnawi UM, El-Tantawy SI. The effect of alendronate sodium on alveolar bone loss in periodontitis (clinical trial). J Int Acad Periodontol 2003;5:510.
  • 56
    Jeffcoat MK. Safety of oral bisphosphonates: controlled studies on alveolar bone. Int J Oral Maxillofac Implants 2006;21:349353.
  • 57
    Evio S, Tarktila L, Sossa T, et al. Effects of alendronate and hormone replacement therapy, alone and in combination on saliva, periodontal conditions and gingival crevicular fluid matrix metalloproteinase-8 levels in women with osteoporosis. Oral Dis 2006;12:187193.
  • 58
    Rocha ML, Malacara JM, Sánchez-Marin FJ, Vazquez de la Torre CJ, Fajardo ME. Effect of alendronate on periodontal disease in postmenopausal women. A randomized placebo-controlled trial. J Periodontol 2004;75:15791585.
  • 59
    Meraw SJ, Reeve CM. Qualitative analysis of peripheral peri-implant bone and influence of alendronate sodium on early bone regeneration. J Periodontol 1999;70:12281233.
  • 60
    Kajiwara H, Yamaza T, Yoshinari M, et al. The bisphosphonate pamidronate on the surface of titanium stimulates bone formation around tibial implants in rats. Biomaterials 2005;26:581587.
  • 61
    Fugazzotto PA, Lightfoot WS, Jaffin R, Kumar A. Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow-up, and the incidence of complications in two private practices. J Periodontol 2007;78:16641669.
  • 62
    Wang HL, Weber D, McCauley LK. Effect of long-term oral bisphosphonates on implant wound healing: literature review and a case report. J Periodontol 2007;78:548594.
  • 63
    Goss AN, Backhouse P. Medicinal mishap. Bisphosphonates and osteonecrosis of the jaws. Aust Prescr 2007;30:9697.
  • 64
    Ruggerio S, Dodson T, Assael L, et al. American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate-related osteonecrosis of the jaw – 2009 Update. J Oral Maxillofac Surg 2009 (in press).
  • 65
    Khan AA, Sándor GK, Dore E, et al. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2008;35:13911397.
  • 66
    Therapeutic Guidelines: Oral and Dental. 2007 Version 1. Melbourne: Therapeutic Guidelines Limited, 2007:7579.
  • 67
    Marx RE, Sawatari Y, Fortin M, Broumard V. Bisphosphonate-induced exposed bone (osteonecrosis–osteopetrosis) of the jaws. Risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 2005;63:15671575.
  • 68
    Carter G, Doecke C, Goss AN. Bisphosphonates and avascular necrosis of jaws – possible association. Med J Aust 2005;182:413415.
  • 69
    Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S. Osteonecrosis of the jaw induced by orally administered bisphosphonates. Incidence, clinical features, predisposing factors and treatment outcomes.. Osteoporos Int 2007;18:13631370.